To buy shares in United Therapeutics Corporation you will need a US based stock trading platform like Interactive Brokers or Moomoo where it currently costs $580.51 to buy one share in United Therapeutics Corporation (as of 16:00 16-Apr-2026). Which is a change of $2.93 or 0.51% from the last closing price of $577.58.
How To Buy United Therapeutics Corporation Stock
It may seem complicated to buy stock for the first time, but it’s actually very easy. Follow these simple steps to buy shares in United Therapeutics Corporation:
- Pick a stock broker (jump down to compare the best brokers for buying United Therapeutics Corporation stock)
- Deposit funds (bank transfer, ACH, wire transfer, or card)
- Search for the stock symbol: (NASDAQ:UTHR)
- Choose the number of shares you want to buy (1 share currently costs $580.51)
- Click buy (you can either trade immediately at “market” or set a “limit” to buy the stock cheaper if you think the price will go down)
- Track the performance of your United Therapeutics Corporation stock in your account (this will show your profit and loss)
- United Therapeutics Corporation is currently worth $25,442,401,139 based on the last closing price of $577.58 with 2 shares traded.
- The most recent United Therapeutics Corporation daily high has been $581.92 and daily low $573.34.
- The United Therapeutics Corporation stock price 52 week high has been $607.89 and the 52 week low $272.12.
Compare Brokers For Buying United Therapeutics Corporation Stock
It’s usually commission-free to buy US stocks as American stock brokers make their money from payment for order flow. However, there can sometimes be additional charges for buying stocks in an IRA, where your contributions are tax-deductible.
| US Stock Broker | US Stocks Available | Dealing Commission | Margin Rates | Customer Reviews | More Info |
|---|---|---|---|---|---|
 | 17,913 | 0.003% | 5.33% – 6.33% | (Based on 1,372 reviews) | Visit Broker Your capital is at risk |
| 6,000+ | 0% | 0% | (Based on 146 reviews) | Visit Broker Your capital is at risk |
 | 5,000+ | 0% | 8% – 11% | (Based on 0 reviews) | Read Reviews |
| 4,000+ | 0% | 10.2% – 13.2% | (Based on 1 reviews) | Read Reviews |
| 4,000+ | 0% | 8.575% – 13.075% | (Based on 23 reviews) | Read Reviews |
| 5,000+ | 0% | 8% (Flat) | (Based on 24 reviews) | Read Reviews |
| 7,000+ | 0% | 8.5% – 12.075% | (Based on 0 reviews) | Read Reviews |
| 5,000+ | 0% | 9.49% (Flat) | (Based on 0 reviews) | Read Reviews |
Is Now A Good Time To Buy United Therapeutics Corporation Stock?
For stock market analysis, join invesdaq.com, the social network for investors.
- United Therapeutics Corporation’s EPS (earnings per share) are 27.86. A high EPS indicates strong profitability but may already be priced in, while a low EPS could signal weak earnings or a turnaround opportunity, requiring industry comparison.
- United Therapeutics Corporation’s PE (price earnings ratio) is 20.83. A low PE ratio may suggest undervaluation but could also indicate slow growth or risk, whereas a high PE ratio reflects high growth expectations but may signal overvaluation, necessitating a check on earnings sustainability.
The below United Therapeutics Corporation share price analysis and market data includes key financials, earnings estimates, peer performance, dividends, news and a company profile that will give you an indication as to whether this stock is a buy, sell or hold. Subscribe to Good Money Guide Analysis for expert opinion on the latest investment opportunities.